Are CorMedix Inc. (CRMD) stocks a prudent buy?

CorMedix Inc. [CRMD] stock prices are up 2.31% to $3.99 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CRMD shares have gain 7.84% over the last week, with a monthly amount glided 27.88%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

On 10, November 2022, CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update. In a post published today on Yahoo Finance, Conference Call Scheduled for Today at 8:30 a.m. Eastern Time.

From an analyst’s perspective:

CorMedix Inc. [NASDAQ: CRMD] stock has seen the most recent analyst activity on February 17, 2021, when Needham initiated its Buy rating and assigned the stock a price target of $31. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 29, 2020, and set its price target to $22. On September 21, 2020, Truist initiated with a Buy rating and assigned a price target of $20 on the stock. B. Riley FBR started tracking the stock assigning a Buy rating and suggested a price target of $48 on December 18, 2019. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $15 on March 26, 2019. ROTH Capital started tracking with a Buy rating for this stock on December 06, 2018, and assigned it a price target of $6. In a note dated September 25, 2017, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $3 to $4.

The stock price of CorMedix Inc. [CRMD] has been fluctuating between $2.64 and $8.02 over the past year. Currently, Wall Street analysts expect the stock to reach $15.00 within the next 12 months. CorMedix Inc. [NASDAQ: CRMD] shares were valued at $3.99 at the most recent close of the market. An investor can expect a potential return of 275.94% based on the average CRMD price forecast.

Analyzing the CRMD fundamentals

The most recent quarter, CorMedix Inc. [NASDAQ:CRMD] reported sales of 6.8 million, representing a drop of -82.10%. Gross Margin for this corporation currently stands at -10.42% with Operating Margin at -15417.51%, Pretax Margin comes in at -15429.47%, and Net Margin reading is -14774.70%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.87 points at the first support level, and at 3.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.07, and for the 2nd resistance point, it is at 4.16.

CorMedix Inc. [CRMD] reported earnings per share of -$0.19 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.21/share, meaning a difference of $0.02 and a surprise factor of 9.50%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.18 per share as compared to estimates of -$0.22 per share, a difference of $0.04 representing a surprise of 18.20%.

Ratios To Look Out For

It’s worth pointing out that CorMedix Inc. [NASDAQ:CRMD]’s Current Ratio is 11.80. Further, the Quick Ratio stands at 12.43, while the Cash Ratio is 12.27. Considering the valuation of this stock, the price to sales ratio is 897.58, the price to book ratio is 2.76.

Transactions by insiders

Insider trading, which has resulted in 1 insider purchases of 4,700 shares and 0 insider sales of 0 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Todisco Joseph, Chief Executive Officer, that happened on Nov 15 when 20000.0 shares were purchased. Chief Executive Officer, Todisco Joseph completed a deal on Aug 24 to buy 4700.0 shares. Meanwhile, Director Kaplan Myron bought 5000.0 shares on May 17.